Oscar Health Inc

OSCR is in a Stage 2 advance confirmed by a recent momentum breakout, but price is currently consolidating just above the rising 9/20 EMAs and horizontal breakout zone in overbought territory. Medium-term bias remains bullish on rising EMAs and structural breakout, yet short-term timing is unclear until a defined pullback or continuation signal emerges. Preferred engagement is deferred, stalking for pullbacks into the confluence of the 9EMA/20EMA or prior resistance as support.

• ↑Q2 revenue $4.9B (+70% YoY); H1 net income $1B.
• ↑Membership grows 46% to 2.96M, boosting ACA market share.
• ↓Insider sales drove 3.8% share drop; flagged 31.7% overvaluation.